Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
ANGLE shares surge 58% after gaining US regulatory approval

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
After six long years of gathering data and evidence ANGLE’s (AGL:AIM) liquid biopsy platform Parsortix was given regulatory approval from the US Federal Drug Administration for use in the detection of metastatic breast cancer.
Although it has been a long wait for investors FDA approval is a significant milestone for ANGLE and has the potential to unlock a multi-billion market opportunity.
FDA approval de-risks uncertainty priced into the shares which surged 58% on the day of the announcement (25 May).
Taking tissue biopsies is expensive and bears the risks of side-effects and often the type of cancer is misdiagnosed.
The parsortix system extracts circulating cancer cells from a simple blood sample, reducing the cost, complexity, and risks of diagnosing cancers.
Berenberg’s analysts believe validation of the technology will increase the number of clinical studies into different cancers as well as accelerate the company’s pharmaceutical services franchise. Here, cancer cells are extracted to gain insights in drug trials.
Demonstrating the momentum, ANGLE announced (30 May) it has signed a clinical study agreement with Solaris Health, the largest US urology network comprising 179 clinics.
Berenberg said the high-profile deal should give ANGLE ‘significant commercial muscle’ to market the Parsortix system for prostate cancer.
The investment bank estimates prostate cancer is ANGLE’s largest addressable market worth around $5 billion in the US alone.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.
Our website uses cookies to give you a better browsing experience.
You can choose to accept all cookies, or control which we use by clicking 'Manage cookies'. To learn more, read our cookie policy.